At the news
? BEARISHIMPACT 6/10 8-K filed Sep 2, 2026 at 16:05 ET
Phreesia reported Q2 FY2027 revenue of $129.5M (+10% YoY), in line with consensus, but GAAP EPS of $0.03 was a significant miss vs the $0.10 Street consensus. The company maintained its lowered FY2027 revenue guidance of $510-520M and EBITDA guidance of $125-135M, citing ongoing variability in network solutions revenue from pharma budget pullbacks. A restructuring plan eliminating ~220 positions was implemented in May 2026, with $2.8M in charges recognized this quarter. The stock faces headwinds from the EPS miss, guided revenue deceleration, and a history of poor post-earnings performance.
- Total revenue of $129.5M, up 10% YoY, in line with consensus of $129.0M
- GAAP diluted EPS of $0.03, missing Street consensus of $0.10 by ~70%
- Subscription revenue declined 2% YoY to $52.7M; payment solutions grew 36% to $38.5M; network solutions grew 9% to $38.3M
- FY2027 revenue guidance maintained at $510-520M (implying ~flat to -3% YoY at midpoint), lowered from prior $545-559M in March 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access